COMUNICADO: Un estudio muestra la correlación entre un subtipo de cancer de pulmón y los resultados del tratamiento (y 2)

[TAB]

(1) Peterson P, Park K, Fossella F, et al. Is Pemetrexed More Effective

in Adenocarcinoma and Large Cell Lung Cancer than in Squamous Cell

Carcinoma? A Retrospective Analysis of a Phase III Trial of

Pemetrexed vs Docetaxel in Previously Treated Patients with Advanced

Non-small Cell Lung Cancer (NSCLC). Abstracto # 6521, 14 Conferencia

Europea Sobre el Cáncer (ECCO).

(2) Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial

of pemetrexed versus docetaxel in patients with non-small cell lung

cancer previously treated with chemotherapy. J Clin Oncol 2004;

22:1589-97.

(3) Sigmond J Backus HH, Wouters D, et al. Induction of resistance to the

multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon

cancer cells is associated with thymidylate synthase overexpression.

Biochem Pharmacol 2003; 66:431-38.

(4) Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the

lung compared to other histotypes shows higher messenger RNA and

protein levels for thymidylate synthase. Cancer 2006; 107:1589-96.

(5) National Cancer Institute, "General Information About Non-Small Cell

Lung Cancer", Modificado el 2 de agosto de 2007.

http://www.cancer.gov/cancertopics/pdq/treatment/

non-small-cell-lung/patient

(Acceso desde el 11 de septiembre de 2007).

(6) American Cancer Society, "What is non-small cell lung cancer?",

Modificado el 25 de octubre de 2006.

http://www.cancer.org/docroot/CRI/

content/CRI_2_4_1x_What_Is_Non-Small_Cell_Lung_Cancer.asp?sitearea=

(Accessed Sept. 18, 2007).

(7) Okabe T, Nakagawa K, Kuboto K, et al. Prognostic factors affecting

survival on pretreated patients with locally advanced or metastatic

non-small cell lung cancer (NSCLC) - Subgroup analysis in a

randomized Ph. II study of pemetrexed 500 mg/m2 and 1000 mg/m2.

Abstract # P-6560, 14th European Cancer Conference.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

[FTAB]

Gregory L. Clarke de Eli Lilly and Company, + 1-317-554-7119 (móvil), gregory.clarke@lilly.com; o Paul George de CPR Worldwide, +1-917-251-1038 (móvil), p.george@cprworldwideusa.com, para Eli Lilly and Company /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, photodesk@prnewswire.com